<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071459</url>
  </required_header>
  <id_info>
    <org_study_id>12 554 01</org_study_id>
    <secondary_id>12-018-0200</secondary_id>
    <nct_id>NCT02071459</nct_id>
  </id_info>
  <brief_title>Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA</brief_title>
  <acronym>DOPS-AMS</acronym>
  <official_title>Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effects of L-Threo DOPS on orthostatic hypotension symptoms and other non-motor&#xD;
      symptoms in patients with Multiple System Atrophy (MSA) after 12 weeks following&#xD;
      randomization to continued therapy with droxidopa or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background :&#xD;
&#xD;
      Multiple system atrophy (MSA) is a rare, sporadic progressive neurodegenerative disorder,&#xD;
      rapidly leading to severe disability and impairment of quality of life. MSA is characterized&#xD;
      by a variable combination of a poor levodopa parkinsonism and /or cerebellar ataxia and&#xD;
      autonomic failure (cardiovascular and / or bladder and sexual dysfunction) (Gilman et al,&#xD;
      2008). The prevalence is approximately 4-5 cases per 100 000 inhabitants.&#xD;
&#xD;
      Orthostatic hypotension (OH) is one of the major symptoms of MSA, present in a large majority&#xD;
      of patients, leading to significant disability because of impaired balance, falls and&#xD;
      possibly syncope. Drugs available to treat OH in this disease are very limited.&#xD;
&#xD;
      L-ThreoDOPS (L DOPS or DroxiDopa) is an orally administered synthetic catecholamine acid that&#xD;
      is converted to the sympathetic neurotransmitter norepinephrine (NE) through a single step of&#xD;
      decarboxylation by the endogenous enzyme 3,4-dihydroxyphenylalanine (DOPA) decarboxylase. It&#xD;
      prevents symptoms related to OH by central and/peripheral mechanisms. This drug is currently&#xD;
      developed for &quot;neurogenic OH&quot; by Chelsea Therapeutics on the basis of short duration&#xD;
      placebo-controlled randomized trials. Besides an expected effect on OH, L-DOPS may also, by&#xD;
      noradrenergic stimulation, improve some motor and non-motor symptoms common and disabling in&#xD;
      MSA patients such as akinesia and fatigue.&#xD;
&#xD;
      In this context, the French reference center for MSA and the 12 national centers with&#xD;
      identified skills to manage this disease, propose to conduct a national multicenter&#xD;
      randomized clinical trial versus placebo to evaluate the long term efficacy (3 months) of&#xD;
      L-threo DOPS on the OH and other non-motor symptoms in MSA patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2014</start_date>
  <completion_date type="Actual">October 28, 2019</completion_date>
  <primary_completion_date type="Actual">October 28, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of long term efficacy of L-threo DOPS</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the efficacy of long term efficacy of L-threo DOPS (droxidopa) in MSA patients (probable or possible - cerebellar (C) or parkinsonian (P) type) with symptomatic NOH as measured by the relative change in mean score of Orthostatic Hypotension Symptom Assessment (OHSA) (Part I of the questionnaire on the symptoms OH (OHQ) (Kaufmann et al., 2011)) 12 weeks following randomization to therapy with droxidopa or placebo (including 8 weeks to maximum tolerated dose).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of L-ThreoDOPS on symptomatic OH</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate and compare the efficacy of L-ThreoDOPS on symptomatic OH (measured by the relative change in mean score of Item 1 of the Orthostatic Hypotension Symptom Assessment (OHSA)) in MSA patients 4, 8 and 12 weeks following randomization to continued therapy with droxidopa or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effects of L-Threo DOPS on motor symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the effects of L-Threo DOPS on motor symptoms (UMSARS I and II) in MSA patients after 12 weeks following randomization to continued therapy with droxidopa or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of L-Threo DOPS on dysautonomic symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the effect of L-Threo DOPS on dysautonomic symptoms (COMPASS) in MSA patients after 4, 8 and 12 weeks following randomization to continued therapy with droxidopa or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of high doses of L-ThreoDOPS</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Determine the safety of high doses of L-ThreoDOPS in MSA patients based on the occurrence of treatment-emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>L-Threo DOPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with L-Threo DOPS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Threo DOPS</intervention_name>
    <description>initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose</description>
    <arm_group_label>L-Threo DOPS</arm_group_label>
    <other_name>L DOPS or DroxiDopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>initial period (4 weeks) followed by 8 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MSA patients (possible or probable, MSA-P or C (according to revised criteria, Gilman&#xD;
             et al 2008)).&#xD;
&#xD;
          -  Aged 30 to 80 years,&#xD;
&#xD;
          -  Able to walk at least 10 meters&#xD;
&#xD;
          -  With symptomatic OH (score of at least 3 at one of the items of Part I of the OH scale&#xD;
             (OHQ))&#xD;
&#xD;
          -  Documented fall in systolic blood pressure of at least 20 mmHg, and/or in diastolic&#xD;
             blood pressure of at least 10 mmHg, within 3 minutes after standing.&#xD;
&#xD;
          -  Able to fill in the evaluation questionnaires with or without help&#xD;
&#xD;
          -  With no significant problems with swallowing.&#xD;
&#xD;
          -  Stable anti-parkinsonian, dysautonomia and depression treatments for the 4 weeks&#xD;
             before the study and during the entire study&#xD;
&#xD;
          -  Signed written informed consent for the present study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia (DSM-IV, Mini-Mental State Examination (MMSE) &lt; 24/30)&#xD;
&#xD;
          -  Concomitant use of vaso-constrictive drugs, other than midodrine. Patients taking&#xD;
             vasoconstrictor agents such as ephedrine, dihydroergotamine, must stop taking these&#xD;
             drugs at least 2 days or 7 half-lives prior to their baseline visit (Visit 1); the&#xD;
             association with midodrine may be kept at a stable dose not exceeding 3 tablets (7.5&#xD;
             mg) / day if the patient has no CV history. This will be discussed case by case with&#xD;
             the coordinating center and the safety committee of this study.&#xD;
&#xD;
          -  Taking anti-hypertensive medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne PAVY-LE-TRAON, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital G. &amp; R. Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>chu de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 21, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L-threo DOPS (DroxiDopa)</keyword>
  <keyword>Orthostatic Hypotension</keyword>
  <keyword>Multiple system atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Droxidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

